

**REMARKS/ARGUMENT**


This Preliminary Amendment is being submitted to change the multiple dependent claims to single dependent claims in order to eliminate the improper multiple dependent claims and to reduce the government filing fee.

**EXPRESS MAIL CERTIFICATE**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label # EL855845511US) in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231, on August 17, 2001:

Dorothy Jenkins

Name of Person Mailing Correspondence


  
Signature

August 17, 2001

Date of Signature

EAM/jc

Respectfully submitted,

  
Edward A. Meilman  
Registration No.: 24,735  
OSTROLENK, FABER, GERB & SOFFEN, LLP  
1180 Avenue of the Americas  
New York, New York 10036-8403  
Telephone: (212) 382-0700

**APPENDIX B**  
**VERSION WITH MARKINGS TO SHOW CHANGES MADE**  
**37 C.F.R. § 1.121(b)(iii) AND (c)(ii)**

**CLAIMS:**

5. A pharmaceutical preparation according to [claims 1 to 4] claim 1 characterised in that the percentage ratio between the lactate and glycolate units in the lactic-co-glycolic copolymer varies between 100% and lactate and 90% of glycolate, both inclusive.

6. A pharmaceutical preparation according to [any of the previous claims] claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of LHRH.

8. A pharmaceutical preparation according to [claims 1 to 5] claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is somatostatine or an analogue thereof.

10. A pharmaceutical preparation according to [claims 1 to 5] claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of human calcitonine.